	US 12,083,098 B2
	Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
Torry A. Tucker, Tyler, TX (US); and Steven Idell, Tyler, TX (US)
Assigned to ACTUATE THERAPEUTICS INC., Fort Worth, TX (US)
Appl. No. 17/056,238
Filed by Actuate Therapeutics Inc., Fort Worth, TX (US)
PCT Filed May 16, 2019, PCT No. PCT/US2019/032639 § 371(c)(1), (2) Date Nov. 17, 2020, PCT Pub. No. WO2019/222483, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/672,864, filed on May 17, 2018.
Prior Publication US 2021/0212988 A1, Jul. 15, 2021
Int. Cl. A61K 31/407 (2006.01); A61K 9/00 (2006.01); A61P 11/00 (2006.01)

CPC A61K 31/407 (2013.01) [A61K 9/0073 (2013.01); A61P 11/00 (2018.01)]

8 Claims

1. A method of treating idiopathic pulmonary fibrosis (IPF) in a mammalian subject, comprising administering to the mammalian subject, an effective amount of a compound of Formula I

or a pharmaceutically acceptable salt or solvate thereof, wherein:

X is independently —H, halo, 5,6-methylenedioxy, —CN, —OMe, —OH, —OBn, —CF₃, —CH₂OH, —CH2OMe, —CH₂CH₂CO₂H, or —CH₂CH₂CO₂Et;

R¹is —H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with —NH₂;

R²is —H, lower alkyl, lower alkyl substituted with a hydroxy, or lower alkyl substituted with —NH₂; and

Y is independently —H, halo, —OMe, —OH, —OBn, —CF₃, —CH₂OH, —CH₂OMe, —NO₂, —CN, or —C═CH₂.